Atea Pharmaceuticals, Inc.
AVIR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001593899
No open-market purchases or sales by Atea Pharmaceuticals, Inc. insiders were filed in the last 90 days; 124 institutions reported holding it in 13F filings for Q2 2026, worth $276.4M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Atea Pharmaceuticals, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Of which not filed for Q4 2023 | Q4 2023 | Change |
|---|---|---|---|---|
| Holders | 119 | 1 | 108 | −10 |
| Shares | 56.9M | 1.26M | 55.1M | −500.6K (−0.9%) |
| Value | $170.6M | $3.78M | $168.3M | +$1.47M (+0.9%) |
1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (11)
Institutions that held Atea Pharmaceuticals, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna Portfolio Strategies, LLC | 83,275 | $254.0K | 0.00% |
| Brevan Howard Capital Management LP | 25,717 | $78.4K | 0.01% |
| Wolverine Trading, LLC | 13,874 | $42.3K | 0.00% |
| Rpo LLC | 12,947 | $39.5K | 0.06% |
| Sunpointe, LLC | 11,943 | $36.4K | 0.05% |
| Graham Capital Management, L.P. | 11,387 | $34.7K | 0.00% |
| Rothschild Investment LLC | 3,150 | $9.61K | 0.00% |
| O'Dell Group, LLC | 200 | $610 | 0.00% |
| Frazier Financial Advisors, LLC | 120 | $366 | 0.00% |
| The PNC Financial Services Group, Inc. | 74 | $226 | 0.00% |
| LM Advisors LLC | 50 | $153 | 0.00% |
Sold out (21)
Institutions that held Atea Pharmaceuticals, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Sectoral Asset Management Inc | 600,461 | $1.80M |
| Vontobel Holding Ltd. | 600,461 | $1.80M |
| Bridgeway Capital Management, LLC | 379,912 | $1.14M |
| HRT Financial LP | 71,136 | $213.0K |
| Anson Funds Management LP | 50,000 | $150.0K |
| Squarepoint Ops LLC | 41,308 | $123.9K |
| Pinebridge Investments, L.P. | 38,336 | $115.0K |
| AQR Capital Management LLC | 30,353 | $91.1K |
| Mirae Asset Global Investments Co., Ltd. | 29,926 | $89.8K |
| Virtus ETF Advisers LLC | 24,183 | $72.5K |
| Verition Fund Management LLC | 22,954 | $68.9K |
| Denali Advisors LLC | 18,000 | $54.0K |
| Pinnacle Wealth Planning Services, Inc. | 16,185 | $48.6K |
| Peapack Gladstone Financial Corp | 15,946 | $48.0K |
| Blair William & Co | 10,444 | $31.3K |
| Gladius Capital Management LP | 8,581 | $25.7K |
| Cutler Group LP | 2,400 | $7.00K |
| Lazard Asset Management LLC | 2,298 | $6.00K |
| South State Corp. | 565 | $1.70K |
| Costello Asset Management, INC | 100 | $300 |
| Quent Capital, LLC | 35 | $105 |
Not filed for Q4 2023 yet (1)
Institutions that held Atea Pharmaceuticals, Inc. at the end of Q3 2023 and haven't filed a 13F for Q4 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Tyrus Capital S.A.M. | 1,260,000 | $3.78M |